Ascendis Pharma (ASND) Stock Forecast & Price Target

Ascendis Pharma is supported by a rare-disease portfolio with three commercial growth engines—YORVIPATH, SKYTROFA, and YUVIWEL—that diversify revenue and reduce reliance on any single asset. YORVIPATH already looks like a major cash driver, with revenue reaching €252 million in 2Q26 and >6,300 U.S. enrollments, while non-IFRS operating margin improved to 27% from 22% in 1Q26, signaling strong operating leverage. YUVIWEL adds further upside by entering a proven >$1B achondroplasia market with >220 U.S. enrollments through July 31, >65% reimbursement approval, and a weekly dosing advantage that should support switching, broader adoption, and long-term franchise expansion.

Ascendis Pharma is a commercial and clinical-stage biotechnology company facing elevated execution risk from clinical readouts, regulatory uncertainty, manufacturing issues, and financial pressure, while its growth still depends on broader geographic approvals and label extensions for SKYTROFA, YORVIPATH, and YUVIWEL. Although 2Q26 showed momentum with YORVIPATH up ~26% Q/Q, SKYTROFA up ~24%, and YUVIWEL contributing its first ~$8.8M, near-term downside remains meaningful due to the August ITC initial determination, a potential December Commission decision, and BioMarin’s direct competitive and patent challenge. YUVIWEL also carries accelerated approval risk because final adult height and longer-term safety remain unproven after only two years of data, and weaker confirmatory results or adverse rulings could restrict use, pressure reimbursement, and limit operating leverage.